Literature DB >> 16039064

Amino acids and transaminases activity in ventricular CSF and in brain of normal and Alzheimer patients.

Antimo D'Aniello1, George Fisher, Nicola Migliaccio, Giuseppe Cammisa, Enrico D'Aniello, Patrizia Spinelli.   

Abstract

The present study was conducted to determine the concentration of amino acids in the cerebrospinal spinal fluid (CSF) and the activities of two tramsaminases: glutamic oxaloacetate transaminase (GOT) and glutamic pyruvate transaminase (GPT) in human Alzheimer disease (AD) and normal brain. L-glutamic acid, L-glutamine and L-alanine are the most abundant amino acids in the CSF (50-55% of total amino acids). L-glutamine occurs at much higher levels in Alzheimer CSF compared to the normal CSF (229+/-91.8 nmol/ml in AD versus 107+/-47.2 nmol/ml in normal; P=0.0041). In contrast, L-aspartate occurs at significantly lower concentrations in Alzheimer CSF than normal CSF (46.1+/-25.7 nmol/ml in Alzheimer versus 95.2+/-52.6 nmol/ml in normal; P=0.020). In Alzheimer brain (frontal, parietal and occipital cortices) GOT is present at significantly higher activities than in normal brain cortices (about 1.5 times higher; P<0.01). No significant differences for GPT activity occurred between normal and AD brain. Since CSF receives amino acids from brain tissues, and since GOT catalyzes the conversion of L-aspartate to L-glutamate, the higher concentrations of L-glutamine (which is derived from L-glutamate), and the lower concentrations of L-aspartate found in Alzheimer CSF could be considered as a consequence of the higher activity of GOT that occurs in Alzheimer brain.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16039064     DOI: 10.1016/j.neulet.2005.06.030

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  20 in total

1.  Memantine decreases hippocampal glutamate levels: a magnetic resonance spectroscopy study.

Authors:  Lidia Glodzik; Kevin G King; Oded Gonen; Songtao Liu; Susan De Santi; Mony J de Leon
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2008-02-07       Impact factor: 5.067

2.  Organization of the multiaminoacyl-tRNA synthetase complex and the cotranslational protein folding.

Authors:  Igor N Berezovsky; Zejun Zheng; Atsushi Kurotani; Alexander A Tokmakov; Igor V Kurochkin
Journal:  Protein Sci       Date:  2015-07-14       Impact factor: 6.725

3.  UHPLC-QTOF/MS-based metabolomics investigation for the protective mechanism of Danshen in Alzheimer's disease cell model induced by Aβ1-42.

Authors:  Mingyong Zhang; Yue Liu; Min Liu; Biying Liu; Na Li; Xin Dong; Zhanying Hong; Yifeng Chai
Journal:  Metabolomics       Date:  2019-01-17       Impact factor: 4.290

4.  Oxygen-inducible glutamate oxaloacetate transaminase as protective switch transforming neurotoxic glutamate to metabolic fuel during acute ischemic stroke.

Authors:  Cameron Rink; Surya Gnyawali; Laura Peterson; Savita Khanna
Journal:  Antioxid Redox Signal       Date:  2011-03-28       Impact factor: 8.401

Review 5.  An L-Glutamine Transporter Isoform for Neurogenesis Facilitated by L-Theanine.

Authors:  Yukio Yoneda
Journal:  Neurochem Res       Date:  2017-06-09       Impact factor: 3.996

6.  Family history and TOMM40 '523 interactive associations with memory in middle-aged and Alzheimer's disease cohorts.

Authors:  Auriel A Willette; Joseph L Webb; Michael W Lutz; Barbara B Bendlin; Alexandra M Wennberg; Jennifer M Oh; Allen Roses; Rebecca L Koscik; Bruce P Hermann; N Maritza Dowling; Sanjay Asthana; Sterling C Johnson
Journal:  Alzheimers Dement       Date:  2017-05-23       Impact factor: 21.566

7.  Measurement of glycine in gray and white matter in the human brain in vivo by 1H MRS at 7.0 T.

Authors:  Abhishek Banerjee; Sandeep Ganji; Keith Hulsey; Ivan Dimitrov; Elizabeth Maher; Subroto Ghose; Carol Tamminga; Changho Choi
Journal:  Magn Reson Med       Date:  2012-06-12       Impact factor: 4.668

8.  High performance liquid chromatography determination of L-glutamate, L-glutamine and glycine content in brain, cerebrospinal fluid and blood serum of patients affected by Alzheimer's disease.

Authors:  Tommaso Nuzzo; Andrea Mancini; Mattia Miroballo; Alessia Casamassa; Anna Di Maio; Giorgia Donati; Giulia Sansone; Lorenzo Gaetani; Federico Paolini Paoletti; Andrea Isidori; Paolo Calabresi; Francesco Errico; Lucilla Parnetti; Alessandro Usiello
Journal:  Amino Acids       Date:  2021-02-22       Impact factor: 3.520

9.  Plasma proteomics for the identification of Alzheimer disease.

Authors:  Liang-Hao Guo; Panagiotis Alexopoulos; Stefan Wagenpfeil; Alexander Kurz; Robert Perneczky
Journal:  Alzheimer Dis Assoc Disord       Date:  2013 Oct-Dec       Impact factor: 2.703

10.  The clinical use of blood-test factors for Alzheimer's disease: improving the prediction of cerebral amyloid deposition by the QPLEXTM Alz plus assay kit.

Authors:  Haeng Jun Kim; Jong-Chan Park; Keum Sim Jung; Jiyeong Kim; Ji Sung Jang; Sunghoon Kwon; Min Soo Byun; Dahyun Yi; Gihwan Byeon; Gijung Jung; Yu Kyeong Kim; Dong Young Lee; Sun-Ho Han; Inhee Mook-Jung
Journal:  Exp Mol Med       Date:  2021-06-09       Impact factor: 8.718

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.